Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Portfolio Pulse from
Neurogene Inc. (Nasdaq: NGNE) has provided an update on its Phase 1/2 clinical trial for NGN-401, a gene therapy for Rett syndrome. A serious adverse event (SAE) related to the treatment has emerged in a trial participant.
November 18, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neurogene Inc. has reported a serious adverse event in its NGN-401 gene therapy trial for Rett syndrome, which could impact the trial's progress and investor sentiment.
The emergence of a serious adverse event in a clinical trial can lead to regulatory scrutiny, potential delays, and negative investor sentiment, likely impacting Neurogene's stock negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100